Across TCGA pan-cancer cohorts, CYP4F2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CYP4F2 data layer compared with 19 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CYP4F2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CYP4F2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC and PDAC are the cancer types where CYP4F2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	1.000	0.880	.003	53	view →
PDAC	DFS	Median	All	0.229	0.762	.024	8	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: CYP4F2 tumor-vs-normal RNA expression · all CYP4F2 data types